+ All Categories
Home > Documents > Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD...

Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD...

Date post: 26-Mar-2015
Category:
Upload: lillian-schmidt
View: 221 times
Download: 0 times
Share this document with a friend
Popular Tags:
34
Systematic Review Module Systematic Review Module 10: 10: Quantitative Synthesis Quantitative Synthesis II II Thomas Trikalinos, MD, PhD Thomas Trikalinos, MD, PhD Joseph Lau, MD Joseph Lau, MD Tufts EPC Tufts EPC
Transcript
Page 1: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Systematic Review Module 10: Systematic Review Module 10: Quantitative Synthesis IIQuantitative Synthesis II

Thomas Trikalinos, MD, PhDThomas Trikalinos, MD, PhDJoseph Lau, MDJoseph Lau, MD

Tufts EPCTufts EPC

Page 2: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

CER Process OverviewCER Process Overview

Prepare topic:

· Refine key questions

· Develop analytic frameworks

Search for and select

studies:

· Identify eligibility criteria

· Search for relevant studies

· Select evidence for inclusion

Abstract data:

· Extract evidence from studies

· Construct evidence tables

Analyze and synthesize data:

· Assess quality of studies

· Assess applicability of studies

· Apply qualitative methods

· Apply quantitative methods (meta-analyses)

· Rate the strength of a body of evidence

Present findings

Page 3: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Learning objectives of this moduleLearning objectives of this module

Dealing with between-study Dealing with between-study heterogeneityheterogeneity

Promise and danger of subgroup Promise and danger of subgroup analysesanalyses

Meta-regression Meta-regression Control rate meta-regressionControl rate meta-regression

Page 4: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

HomogeneityHomogeneity

From Cochrane Database Syst Rev. 2000;(2):CD000505

Page 5: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Heterogeneity: Patellar resurfacing Heterogeneity: Patellar resurfacing in total knee arthroplasty for painin total knee arthroplasty for pain

J Bone Joint Surg Am. 2005;87(7):1438-45

Page 6: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

HeterogeneityHeterogeneity

Diversity of studies in a meta-analysis Diversity of studies in a meta-analysis Typically abundant Typically abundant Arguably the most important role of meta-Arguably the most important role of meta-

analytic methodologies is to quantify, analytic methodologies is to quantify, explore, and explain between-study explore, and explain between-study heterogeneity heterogeneity

Page 7: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

HeterogeneityHeterogeneity

Methodological heterogeneityMethodological heterogeneity Pertains to specifics of study design and analysisPertains to specifics of study design and analysis

(e.g., type of study, length of follow-up, proportion of (e.g., type of study, length of follow-up, proportion of dropouts and handling thereof)dropouts and handling thereof)

Clinical heterogeneityClinical heterogeneity Pertains to differences in the populations, intervention and Pertains to differences in the populations, intervention and

co-interventions, outcomes co-interventions, outcomes

Page 8: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Statistical heterogeneityStatistical heterogeneity

Statistical heterogeneity exists when the Statistical heterogeneity exists when the results of the individual studies are not results of the individual studies are not “consistent” among themselves“consistent” among themselves

Clinical heterogeneity

Methodological heterogeneity

Biases

Chance

Statistical heterogeneity

Page 9: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Clinical vs. statistical Clinical vs. statistical heterogeneityheterogeneity

Clinical and methodological heterogeneity is Clinical and methodological heterogeneity is abundant. Our aim is to abundant. Our aim is to exploreexplore it, and use these it, and use these observations to formulate interesting hypotheses.observations to formulate interesting hypotheses.

Often, but not always, clinical and methodological Often, but not always, clinical and methodological heterogeneity will result in a statistically significant testheterogeneity will result in a statistically significant test

Chance, technical issues or biases may result in Chance, technical issues or biases may result in statistically significant results in heterogeneity tests statistically significant results in heterogeneity tests

Page 10: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

D ealing w ith H eterogeneity

H E TE R O G E N E O U STR E A TM E N T E F F E C TS

IGNORE INCORPORATEESTIMATE(insensitive)

EXPLAIN

FIXEDEFFECTS MODEL

DO NOT COMBINEW HEN

HETEROGENEITYIS PRESENT

RANDOMEFFECTS

MODEL

SUBGROUPANALYSES

META-REGRESSION

(control rate,covariates)

Page 11: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Tre

atm

ent

effe

ct

Tre

atm

en

t e

ffect

variable of interest

META-REGRESSION modeling summary data

OVERALL ESTIMATE combining summary data

RESPONSE SURFACE modeling individual patient data

Tre

atm

ent

effe

ct

SUBGROUP ANALYSES differentiating effects in subgroups

Page 12: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Promises of subgroup Promises of subgroup analysesanalyses

Page 13: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

J Am Coll Card 1990

Page 14: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Mortality of thrombolytic therapy for AMI Mortality of thrombolytic therapy for AMI meantime to treatment (0-3 hours)meantime to treatment (0-3 hours)

Page 15: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Mortality of thrombolytic therapy for AMI Mortality of thrombolytic therapy for AMI meantime to treatment (3.1-5 hours)meantime to treatment (3.1-5 hours)

Page 16: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Mortality of thrombolytic therapy for AMI Mortality of thrombolytic therapy for AMI meantime to treatment (5.1-10 hours)meantime to treatment (5.1-10 hours)

Page 17: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Mortality of thrombolytic therapy for AMI Mortality of thrombolytic therapy for AMI meantime to treatment (> 10 hours)meantime to treatment (> 10 hours)

Page 18: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Vit E and all cause mortalityVit E and all cause mortality

Ann Intern Med. 2005;142(1):37-46.

Page 19: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Hazards of subgroup analysesHazards of subgroup analyses

Page 20: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

From Fibrinolytic Therapy Trialists’ Collaborative Group: Indications for Fibrinolytic Therapy Lancet 343: 311,1994

Page 21: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

ISIS-2. Lancet 1988;ii:349-60.ISIS-2. Lancet 1988;ii:349-60.Subgroup analysesSubgroup analyses

Page 22: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

ISIS-2. Lancet 1988;ii:349-60.ISIS-2. Lancet 1988;ii:349-60.Subgroup analysesSubgroup analyses

Page 23: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Beyond subgroup analyses:Beyond subgroup analyses:meta-regressionmeta-regression

Page 24: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Subgroup analysisSubgroup analysis

Ann Intern Med. 2005;142(1):37-46.

Page 25: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Univariate meta-regressionUnivariate meta-regression

Ann Intern Med. 2005;142(1):37-46.

Page 26: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Meta-regression: Zidovudine Meta-regression: Zidovudine monotherapy vs. placebomonotherapy vs. placebo

~τ2 ~τ’2

Page 27: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

# Studies: 40 Var.Btw 23.96 beta se.beta p values Net Change -4.56 9.33 Dose.iso -0.024 0.028 0.40 Dose.prot -0.085 0.080 0.30 Base 0.017 0.062 0.79 Quality 3.10 2.91 0.29 # Studies: 52 Var.Btw 19.08 Net Change -2.16 2.01 Dose.prot -0.096 0.053 0.08 # Studies: 45 Var.Btw 26.80 Net Change 17.20 11.72 Baseline LDL (LDL>130)

-0.138 0.072 0.06

Multivariate meta-regression: Effect of Soy on LDL

Covariate

Ne

t C

ha

ng

e

140 150 160 170 180 190 200

-30

-20

-10

01

0

Covariate

Ne

t C

ha

ng

e

0 20 40 60 80 100

-30

-20

-10

01

0

Dose Baseline LDL

Page 28: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Control Rate Meta-RegressionControl Rate Meta-Regression

Single covariate included is event rate in Single covariate included is event rate in the control group (control rate)the control group (control rate)– Control rate is surrogate for all baseline Control rate is surrogate for all baseline

differences between the studies, in terms differences between the studies, in terms of baseline risk for the event of interest.of baseline risk for the event of interest.

– Can show that underlying risk of event Can show that underlying risk of event (severity of illness) may explain differences (severity of illness) may explain differences in the treatment effect across studiesin the treatment effect across studies

Page 29: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.
Page 30: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.
Page 31: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Control rate meta-regression Control rate meta-regression in the streptokinase examplein the streptokinase example

Stat Med. 1998;17(17):1923-42.

Page 32: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Two types of covariates in meta-Two types of covariates in meta-regressionsregressions

Study level covariates vs. participant level Study level covariates vs. participant level covariates covariates

Study level: presence/absence of Study level: presence/absence of blinding, intervention dose (in blinding, intervention dose (in experimental studies)experimental studies)

Participant level: mean age, proportion Participant level: mean age, proportion of diabetics, mean intake of vitamin D (in of diabetics, mean intake of vitamin D (in observational studies)observational studies)

Page 33: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Spurious associations in meta-Spurious associations in meta-regressions and subgroup analysesregressions and subgroup analyses

Meta-regressions that use participant-level Meta-regressions that use participant-level covariates can mislead, as they are covariates can mislead, as they are susceptible to ecological fallacy susceptible to ecological fallacy

Associations of treatment effect and Associations of treatment effect and participant-level covariates should be participant-level covariates should be interpreted with cautioninterpreted with caution

See the quizSee the quiz

Page 34: Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

SummarySummary

Subgroup analyses, meta-regressions Subgroup analyses, meta-regressions and control-rate meta-regressions are and control-rate meta-regressions are tools to explore between-study tools to explore between-study heterogeneity. Do use them to heterogeneity. Do use them to understand your data. understand your data.

They are mostly hypothesis forming They are mostly hypothesis forming tools. Especially for meta-regressions tools. Especially for meta-regressions on patient-level covariates, ecological on patient-level covariates, ecological fallacy may mislead.fallacy may mislead.

Beware when interpreting their results.Beware when interpreting their results.


Recommended